Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Lunginnov

Lunginnov
2009 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
1 INVESTORS
Description

Manufacturer of laboratory reagents designed for respiratory diseases to make it possible an earlier decision in order to benefit the patient. The company's focus is on detection and study of endothelial dysfunctions and specializes in endocan and cleaved endocan as markers of pulmonary infection/aggression, enabling researchers and clinicians to get medical devices for in vitro diagnostics and for research in life sciences.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Diagnostic Equipment
Primary Office
  • Campus Pasteur, 1 rue du Professeur Calmette
  • 59000 Lille
  • France

+33 03 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Lunginnov’s full profile, request a free trial.

Lunginnov Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Lunginnov Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Autonomie et Solidarité Venture Capital Minority 000 0000 000000 0

Lunginnov Executive Team (2)

Name Title Board
Seat
Contact
Info
Frédéric Joye Chief Executive Officer & President
Philippe Lassalle Scientific Council & Co-Founder